Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells 5,000 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 5,000 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total value of $300,000.00. Following the completion of the transaction, the chief executive officer now owns 293,054 shares of the company’s stock, valued at approximately $17,583,240. This trade represents a 1.68 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

David Alan Campbell also recently made the following trade(s):

• On Tuesday, December 24th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $56.19, for a total transaction of $1,404,750.00.
• On Tuesday, December 3rd, David Alan Campbell sold 15,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $67.00, for a total transaction of $1,005,000.00.
• On Monday, November 25th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $51.60, for a total value of $1,290,000.00.
• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $53.54, for a total value of $1,338,500.00.

Janux Therapeutics Stock Down 12.1 %

JANX stock opened at $50.82 on Thursday. The business’s 50-day moving average price is $54.48 and its 200-day moving average price is $48.16. The stock has a market cap of $2.67 billion, a P/E ratio of -43.44 and a beta of 3.23. Janux Therapeutics, Inc. has a twelve month low of $7.79 and a twelve month high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The firm had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company’s quarterly revenue was down 82.6% compared to the same quarter last year. On average, equities research analysts expect that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a research note on Tuesday, December 3rd. Lifesci Capital upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. UBS Group started coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 price target for the company. Stifel Nicolaus raised their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Finally, Scotiabank increased their price target on Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a report on Wednesday, December 4th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $89.90.

Institutional Investors Weigh In On Janux Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC grew its position in shares of Janux Therapeutics by 0.6% during the third quarter. FMR LLC now owns 7,824,675 shares of the company’s stock worth $355,475,000 after purchasing an additional 47,075 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Janux Therapeutics by 40.0% during the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock valued at $114,587,000 after buying an additional 721,563 shares in the last quarter. Logos Global Management LP raised its position in shares of Janux Therapeutics by 400.0% during the second quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock valued at $31,418,000 after buying an additional 600,000 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Janux Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock worth $30,107,000 after buying an additional 38,490 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its stake in Janux Therapeutics by 190.2% during the third quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock valued at $17,985,000 after acquiring an additional 259,445 shares in the last quarter. 75.39% of the stock is owned by institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.